Celleron Therapeutics

SynOx Therapeutics Ltd, an Irish incorporated clinical stage biopharmaceutical company, has announced the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbion and Gimv.

SynOx, a spin out of oncology company Celleron Therapeutics Ltd, secured exclusive world-wide rights for the clinical development, manufacturing and commercialisation of targeted antibody drug emactuzumab under a licence agreement with Roche.

Philip Lee was delighted to provide Irish law advice to Celleron on the spin out of SynOx and the Series A financing.

Further details available here.

M&A Insights H1 2023 – A cross-border deal insight guide

19 Sep, 2023

Key Contacts: Eoghan Doyle - Partner | Andrew Tzialli - Partner We are delighted to introduce the fifth edition of the Philip Lee M&A Insights guide. In this edition, we review deal activity across H1 2023, and consider the outlook for the rest of the year...

Philip Lee Healthcare, Pharmaceutical and Life Sciences Update Q2 2023

27 Jul, 2023

Key Contacts: Ronan Dunne - Partner | Marie Kinsella - Partner Welcome to the latest update from the Philip Lee Healthcare, Pharmaceutical and Life Sciences group in respect of the second quarter of 2023. To read the full update click here. For further information...

Artificial Intelligence Act – What it means for your business

11 Jul, 2023

Key Contacts: Eoghan Doyle - Partner | Hugo Grattirola - Senior Associate Now that the amended proposal for the regulation of artificial intelligence ("AI") systems (the "Proposed AI Regulation") has been adopted by the European Parliament, we are entering the...

The ‘Study on Familicide and Domestic and Family Violence Death Reviews’.

23 Jun, 2023

Key Contacts: Marie Kinsella - Partner | Anne Bateman - Partner The Minister for Justice, Simon Harris, has published the very important and far reaching report ‘Study on Familicide and Domestic and Family Violence Death Reviews’. It is encouraging to hear the...

The Web3 passport

13 Jun, 2023

Key Contacts: Andrew Tzialli - Partner | Head of blockchain and crypto assets, Andrew Tzialli, spoke to the Web3 passport in their latest podcast to discuss the world of blockchain and digital assets. The Web3 passport podcast explores areas such as Web3, blockchain,...

Mitigating the risk of extinction from AI should be a global priority alongside other societal-scale risks such as pandemics and nuclear war

31 May, 2023

Key Contacts: Sean McElligott - Partner “Mitigating the risk of extinction from AI should be a global priority alongside other societal-scale risks such as pandemics and nuclear war.” Whether you believe the above statement from AI Scientists and Other Notable Figures...

« Older Entries

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Celleron Therapeutics

SynOx Therapeutics Ltd, an Irish incorporated clinical stage biopharmaceutical company, has announced the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbion and Gimv.

Key Contacts

Key Contacts

News and insights

M&A Insights H1 2023 – A cross-border deal insight guide

Philip Lee Healthcare, Pharmaceutical and Life Sciences Update Q2 2023

Artificial Intelligence Act – What it means for your business

The ‘Study on Familicide and Domestic and Family Violence Death Reviews’.

The Web3 passport

Mitigating the risk of extinction from AI should be a global priority alongside other societal-scale risks such as pandemics and nuclear war

Dublin

London

San Francisco